BriaCell Therapeutics Corp. Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: May 17, 2024 · CIK: 1610820
Sentiment: neutral
Topics: material-agreement, corporate-event, filing
Related Tickers: BCTX
TL;DR
BriaCell filed an 8-K on May 14th, looks like a material agreement and other events.
AI Summary
BriaCell Therapeutics Corp. announced on May 14, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing does not specify the details of the agreement or the financial information.
Why It Matters
This 8-K filing indicates significant corporate activity for BriaCell Therapeutics Corp., potentially involving new agreements or financial updates that could impact its stock.
Risk Assessment
Risk Level: medium — 8-K filings can signal important corporate events, but without specific details on the material agreement, the immediate impact and associated risks are unclear.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- Ansell Capital Corp. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by BriaCell Therapeutics Corp. on May 14, 2024?
The filing states that BriaCell Therapeutics Corp. entered into a material definitive agreement on May 14, 2024, but does not provide specific details about the agreement itself.
What other events are reported in this 8-K filing?
The filing indicates 'Other Events' were reported, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this filing?
The filing mentions 'Financial Statements and Exhibits' were included, but the content of these documents is not specified in the provided text.
When was BriaCell Therapeutics Corp. incorporated or organized?
BriaCell Therapeutics Corp. was incorporated or organized in British Columbia.
What was BriaCell Therapeutics Corp.'s former company name?
BriaCell Therapeutics Corp.'s former company name was Ansell Capital Corp., with a date of name change on June 13, 2014.
Filing Stats: 1,476 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-05-17 16:51:55
Key Financial Figures
- $2.00 — re sold at a combined purchase price of $2.00 per Share and accompanying Common Warra
- $1.9999 — re sold at a combined purchase price of $1.9999 per Pre-funded Warrant and accompanying
- $2.215 — re sold at a combined purchase price of $2.215 per Share and accompanying Common Warra
- $0.0001 — rcised in full, at an exercise price of $0.0001 per share. The Common Warrants will be
- $2.11 — ate of issuance at an exercise price of $2.11 per share and will expire on the five y
- $5,000,000, b — ted in gross proceeds to the Company of $5,000,000, before deducting placement agent fees and
- $135,000 — s expenses in an aggregate amount up to $135,000. For certain identified investors, the
- $2.321 — 0 common shares at an exercise price of $2.321 per share. The Placement Agent Warrants
Filing Documents
- form8-k.htm (8-K) — 62KB
- ex4-1.htm (EX-4.1) — 127KB
- ex4-2.htm (EX-4.2) — 125KB
- ex4-3.htm (EX-4.3) — 135KB
- ex5-1.htm (EX-5.1) — 22KB
- ex5-2.htm (EX-5.2) — 16KB
- ex10-1.htm (EX-10.1) — 290KB
- ex10-2.htm (EX-10.2) — 81KB
- ex99-1.htm (EX-99.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 18KB
- ex5-1_002.jpg (GRAPHIC) — 6KB
- ex5-2_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-020460.txt ( ) — 1303KB
- bctx-20240514.xsd (EX-101.SCH) — 4KB
- bctx-20240514_def.xml (EX-101.DEF) — 26KB
- bctx-20240514_lab.xml (EX-101.LAB) — 36KB
- bctx-20240514_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams May 17, 2024 William V. Williams President and Chief Executive Officer